About the NCBPNG Steering Committee
Current Team
Andrew joined the NCBPNG Steering Committee in 2017. He is a Cancer Research Scientist at UNC-CH.
Keishea joined the NCBPNG Steering Committee in 2022.
Matt joined the NCBPNG Steering Committee in 2023.
DJ joined the NCBPNG Steering Committee in 2023.
Theresa joined the NCBPNG Steering Committee in 2022.
Marty O’Boyle currently serves as the Head of Consulting – North America for Koerber-Pharma, which specializes in pharma engineering consulting for life science manufacturing companies. He is also the founder and president of Sandpiper Technical Solutions, a full service solutions provider for biopharma laboratory automation. Marty started his engineering career as an applications engineer specializing in pneumatic, hydraulic, and electromechanical design. In 1999, he joined Klockner-Medipak Inc, in Clearwater, FL (now Koerber-Pharma) as a packaging machinery project engineer. Over a twenty-year period he fulfilled a variety of roles in service to Koerber’s clients in the life sciences market (Project Engineer, Project Manager, Validation Engineer, Technical Sales Director, and Technical Director for North American Operations). In 2019, Marty founded Sandpiper to expand into the growing field of life science automation, at the laboratory scale. Marty joined the NCBPNG Steering Committee in 2022.
Pratik joined the NCBPNG Steering Committee in 2024.
Matt Troskey is a Director of Business Development at Medicilon, a leading CRO providing fully integrated pharmaceutical R&D services for global pharma. He is passionate about pushing the boundaries of drug discovery and development, from small molecules to biologics, peptides, ADCs, cell and gene therapies. Matt’s expertise spans custom synthesis, medicinal chemistry, biology and bioanalysis, pharmacology, DMPK, PD, toxicology, CMC services, formulation, process development, and manufacturing.
At Medicilon, Matt builds powerful partnerships and delivers top-tier solutions to overcome the toughest R&D challenges. Whether it’s navigating IND-enabling studies, scaling up manufacturing, or providing regulatory support, he is committed to accelerating drug development pipelines and reducing time to market. Together, we can transform bold ideas into breakthrough therapies that change lives.